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Response to Reviewers’ Comments 
Reviewer #1:  
1. The short paper would benefit from footnoting the citations from the literature in the 
journal style. 
We have amended the citations in the manuscript so that they adhere to the journal style. 
Reviewer #2: 
1. In this paper the authors outline their approach to development of the SPaRQ, which 
seems good. The SPaRQ has not been applied widely though so there are no data across 
different centres that support the tool. I guess the idea is to present it and hope that it will be 
studied further in the future.  
To address this comment, we have clarified in the manuscript our reasons for choosing to 
outline the development of the SPaRQ, despite the fact that it is a new tool and thus has not 
yet been widely used (Page 3, Lines 131-136). Specifically, the purpose of presenting the SPaRQ 
was to provide a case study of the utilisation of best practice questionnaire development 
techniques. The use of such techniques, particularly qualitative research with patients and 
Rasch analysis, to develop questionnaires remains rare in the field of hearing research. 
Therefore, the SPaRQ is a unique example of the multi-stage, multi-method process necessary 
for designing a high quality questionnaire.  
2. One must wonder whether another questionnaire tool is really needed. Rather than 
increasing knowledge, it is quite possible that adding more tools just dilutes the applicability 
of the whole field, but that remains to be seen. 
We have amended the manuscript by acknowledging that a limitation of this research is that it 
adds another questionnaire to the range of existing questionnaires that are currently being 
used in hearing research. In addition, we have stated that it is sometimes necessary to develop 
new measures, like the SPaRQ, in order to address the lack of gold standard measures in this 
field. Finally, we have proposed that what is needed is guidance for researchers and clinicians 
to help them choose a suitable measure from the range available to them (Page 4, Lines 179-
185).  
EDITORIAL COMMENTS: 
1. Minimal revisions are required for this paper, but the references cited within the text do 
need to be updated to the journal's reference style.  Within the text, each reference should 
be cited using its corresponding number from the main reference list.   
We have amended the references cited in the manuscript so that they adhere to the journal 
style. 
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REVIEW ARTICLE 1 
 2 
How do we know that our patients have benefitted from our ENT/Audiological 3 
interventions? 4 
 5 
ABSTRACT 6 
 7 
This short review article gives an introduction to some of the fundamental concepts and 8 
challenges facing measurement in hearing healthcare practice and research. The impact 9 
of hearing loss almost always extends beyond the sensory impairment itself, even when 10 
the measured degree of audiometric loss is mild. Yet, going beyond audibility, into the 11 
realm of measuring impact, takes us into a much more complex and less well-defined 12 
space. How does one therefore best measure the therapeutic benefit for evaluating 13 
efficacy or for clinical practice audit? Three case studies illustrate approaches to 14 
overcome such challenges. Each example highlights the importance of thinking critically 15 
about what it is one is seeking trying to measure, rather than selecting a questionnaire 16 
instrument based simply on its popularity or accessibility. We conclude by highlighting 17 
the important role that clinicians can play in collecting clinical data about their preferred 18 
instruments so that we have some evidence to inform decisions about good practice 19 
(content validity etc). We would also strongly support open data sharing as we believe 20 
that this is one of the best ways to make the most rapid progress the field. 21 
 22 
 23 
INTRODUCTION  24 
 25 
The purpose of this short article is to introduce the reader to some of the fundamental 26 
concepts and challenges facing measurement in healthcare practice and research. The 27 
concept of measurement will perhaps be most familiar to the reader in the context of the 28 
audiogram. The audiogram plots air conduction threshold for tones presented to either 29 
ear and is useful for determining hearing sensitivity. Pure-tone averages can be 30 
interpreted with respect to standard category boundaries, such as mild hearing loss (26-31 
40 dB A) (1). The impact of hearing loss almost always extends beyond the sensory 32 
impairment itself, even when the measured degree of audiometric loss is mild. It is well 33 
known that residual hearing is not related in any straightforward way to the burden of 34 
disability experienced by a person with hearing loss (2). Going beyond audibility, into the 35 
realm of measuring impact, takes us into a much more complex and less well-defined 36 
space. For example, mild-to-moderate hearing loss has been reported by patients to 37 
interfere with hearing environmental sounds, listening, communicating, speaking, and it 38 
can negatively affect family life, social relationships, and ability to work. On a personal 39 
level, the negative stigma can affect personal identity, promote a sense of isolation, 40 
negative emotions such as frustration, distress and depression. Hearing loss can also 41 
increase the effort required for listening and communicating causing fatigue (3). The 42 
impact of hearing-related problems, such as tinnitus, similarly spans a wide array of 43 
psychological and social dimensions (4). 44 
 45 
No gold standard measure Instead of clinician-administered tests, the impacts of 46 
hearing loss and tinnitus are often assessed using a patient-reported instrument such as 47 
a questionnaire. However, there are no gold standards. This is reflected in the lack of 48 
consensus in the selection of questionnaires for hearing studies (4, 5).  49 
 50 
Diversity of patient complaints Given the diversity of reported complaints, every 51 
patient presents with a complex array of symptoms and functional impacts. Moreover, 52 
any clinician or researcher who has worked with people with a hearing-related problem 53 
will appreciate that every individual’s experience is a very personal one. In practical 54 
terms, while one person’s primary motivation for seeking medical help might be because 55 
their hearing-related problem means that they no longer enjoy socialising with friends 56 
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down the pub, for another it may be because their ability to play in an orchestra is 57 
hindered, while for another hearing loss might make it difficult watching television 58 
comfortably with their spouse. The impact of hearing loss is therefore a construct that is 59 
very individualised and personal. 60 
  61 
Practical challenges This situation presents the ENT/Audiology professional with two 62 
major practical challenges; the first concerns how to comprehensively assess a patient 63 
for a precise clinical diagnosis, and the second concerns how to measure the therapeutic 64 
benefit for evaluating efficacy or for clinical practice audit. With some degree of success, 65 
the challenge for clinical diagnosis has been resolved by creating multi-attribute 66 
questionnaire instruments whose scores can be used to discriminate between individuals. 67 
For example, the Hearing Handicap Inventory for the Elderly (HHIE) asks 25 questions 68 
about the emotional consequences of hearing impairment, social and situational effects 69 
(6), with pre-defined cut-offs for determining “no handicap”, “mild to moderate 70 
handicap” and “significant handicap”.  71 
 72 
However, the solution to the first challenge tends to be incompatible with evaluating 73 
therapeutic benefit. This is because questionnaire items that discriminate well between 74 
different patients at the diagnostic appointment are not necessarily sensitive to 75 
evaluating changes over time within the same patient (7). And it is difficult to design a 76 
questionnaire instrument that is both discriminative and evaluative. To illustrate this with 77 
an example, tinnitus-related emotional distress and auditory difficulties might both 78 
discriminate one patient from another, but only one of these might be responsive to 79 
treatment (e.g. hearing aids should reduce auditory difficulties, but might not reduce 80 
distress). Averaging the benefit scores for these components could therefore compromise 81 
the sensitivity of an aggregated score to measuring treatment-related change. As a 82 
general rule, questionnaire instruments that successfully measure therapeutic benefit in 83 
different situations tend to be those with good statistical properties that enable the 84 
clinician or investigator to interpret specific complaints rather than a global non-specific 85 
construct like “severity” or “handicap” (8). 86 
 87 
In this short review, we present three case studies which illustrate approaches to 88 
overcome the challenges of evaluating therapeutic benefit. These examples highlight the 89 
need to think critically about what it is one is seeking trying to measure, rather than 90 
selecting a questionnaire instrument based simply on its popularity or accessibility.  91 
 92 
Measuring psychosocial functioning of adults with mild-to-moderate hearing 93 
loss 94 
 95 
The International Classification of Functioning, Disability, and Health (ICF) is a 96 
biopsychosocial framework designed to standardise the description, measurement, 97 
clinical assessment, and teaching of functioning, disability, and health for researchers, 98 
clinicians, clinical educators, and policy-makers around the world (9). The ICF consists of 99 
three primary domains of patient burden: (1) physical impairments, or deficits in body 100 
functions or body structures, (2) activity limitations, or problems executing tasks and 101 
actions, and (3) participation restrictions, or problems with involvement in life situations. 102 
These domains are influenced by both environmental factors and personal factors (9, 103 
10). The ICF also includes a comprehensive taxonomy of categories of functioning (e.g. 104 
listening, education, self-care). The categories of functioning most relevant to hearing 105 
loss have been identified by a large, cross-cultural, mixed-methods study (10). 106 
Therefore, the ICF could be used in the future to standardise the measurement of 107 
individuals with hearing loss in clinical practice or in research.  108 
 109 
The domain of participation restrictions is thought to be the most difficult of the ICF 110 
domains to measure (11). One obstacle is that the conceptualisation of participation 111 
restrictions is imprecise and inconsistent (12). The WHO (2001) definition above is rather 112 
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broad, which means that it is difficult to distinguish participation restrictions from related 113 
constructs, such as activity limitations and quality of life (13). Also, there is no consensus 114 
regarding the categories of functioning that should be included in a participation 115 
restrictions measurement instrument (14). Another obstacle is that different people 116 
participate in different ways, depending on their personal preferences and circumstances. 117 
It is difficult to capture such a highly individual construct in one standardised tool (13). 118 
One solution is to develop different questionnaire instruments for different subgroups 119 
(15). However, this can impede comparisons across groups and across studies. Another 120 
solution is to create patient-generated measurement tools that permit respondents to 121 
personalise their content. However, personalised instruments may not be well suited to 122 
the grouping of scores or comparisons across time periods and across individuals. Also, 123 
they can be difficult for some respondents to understand and complete (16). Another 124 
approach is to obtain counts of social interaction frequency or social network size (17). 125 
However, such measures fail to acknowledge that the quality of social contacts can be 126 
more important for wellbeing than quantity of social contacts (18).  127 
 128 
** insert Table 1 about here ** 129 
 130 
Here, we provide a case study of the utilisation of best practice techniques to develop a 131 
hearing-specific measure of participation. Best practice techniques, which include 132 
qualitative methodologies (e.g. cognitive interviews) and modern psychometric analysis 133 
(e.g. Rasch analysis), are necessary for the creation of gold standard measures. 134 
However, to date, these techniques have seldom been employed in the development of 135 
hearing-specific measures. 136 
 137 
The questionnaire we developed, entitled the Social Participation Restrictions 138 
Questionnaire (SPaRQ), was designed to serve as an outcome measure in either research 139 
or clinical practice. The SPaRQ consists of a 9-item subscale measuring social behaviours 140 
(e.g. difficulties with social interactions) and a 10-item subscale measuring social 141 
perceptions (e.g. feelings of isolation). It uses an 11-point response scale (0=completely 142 
disagree, 10=completely agree) because a broad range of response options are 143 
considered to enhance responsiveness (19). The SPaRQ was designed by conducting a 144 
series of qualitative and quantitative studies (see Table 1) in accordance with 145 
internationally-recognised guidelines from the questionnaire development literature (20, 146 
21). Our aim was to ensure that the measurement properties of the SPaRQ met the 147 
standards required of outcome measures used in clinical practice and in clinical trials 148 
(21). 149 
 150 
The first step was to create a precise conceptual model of hearing-related participation 151 
restrictions and to determine the categories of functioning that should be included in the 152 
measure by (1) reviewing the literature, including existing questionnaire instruments and 153 
the ICF, and (2) interviewing adults with hearing loss and hearing healthcare 154 
professionals (22). The second step was to evaluate the content validity of the SPaRQ, 155 
including its relevance, clarity, acceptability, and potential responsiveness, by (1) 156 
conducting cognitive interviews with adults with hearing loss and (2) surveying hearing 157 
healthcare professionals. Qualitative research with key stakeholders is an often 158 
overlooked but essential component of questionnaire development, at it ensures that the 159 
instrument adequately captures the respondents‘ experiences, uses everyday language, 160 
and is easy to administer and complete (23). The third step was to assess the 161 
psychometric properties of the SPaRQ by applying (1) Rasch analysis and (2) traditional 162 
(i.e. Classical Test Theory) psychometric analysis to data collected from adults with 163 
hearing loss. Whilst most hearing-specific questionnaires have been developed using 164 
traditional psychometric analysis alone, a modern approach (i.e. Rasch analysis or Item 165 
Response Theory) should also be applied because it enables all the relevant psychometric 166 
properties (e.g. unidimensionality, differential item functioning) to be adequately 167 
assessed (24). The outcome of this rigorous development process was the production of 168 
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a questionnaire that possesses an array of good measurement properties. For instance, 169 
each subscale was found to be unidimensional, which means that all of the items within a 170 
subscale measure the same construct, and well-targeted, which means that the 171 
subscales have high measurement precision and capture a wide range of participation 172 
restrictions. There was also evidence to support the convergent validity of the subscales 173 
with each one displaying strong, positive correlations with a hearing-specific disability 174 
measure and moderate, positive correlations with a generic disability measure and a 175 
mental health screening tool. Responsiveness of the SPaRQ is yet to be examined, but 176 
this is planned for future research. 177 
 178 
One limitation of this research is that it adds another questionnaire to the range of 179 
existing questionnaires that are currently being used in hearing research (5). However, it 180 
is sometimes necessary to develop new measures in accordance with the latest best 181 
practice recommendations in order to address the lack of gold standard measures in the 182 
field. In the future, researchers and clinicians would benefit from the introduction of 183 
guidelines to help them to identify high quality measures that are appropriate for their 184 
purposes.   185 
 186 
 187 
Relevance of existing questionnaires for assessing burden of single-sided 188 
deafness (SSD) 189 
 190 
At face value, single-sided deafness (SSD) would appear to be a form of hearing loss 191 
where the task of determining whether or not a patient has benefitted from an 192 
intervention should be relatively straightforward. Lack of hearing on one side of the head 193 
would be expected to hinder access to acoustic information in that hemifield and disrupt 194 
the ability to segregate information from different sources (25). One might also be 195 
tempted to assume that relevant interventions for this patient group are those that 196 
address these impaired listening skills, and benefit should be measured in terms of the 197 
extent to which they have restored or improved such skills. However, some of the 198 
earliest published observations about these patients remarked on the unexpected degree 199 
of burden that impairments to these listening skills impose on the patient. Harford and 200 
Barry noted “the persistence and earnestness of reports from unilaterally hearing-201 
impaired individuals stating serious difficulty encountered in many common listening 202 
situations” (26). Early work also suggested a breadth and depth of burden that one might 203 
not predict from these functional difficulties. Giolas and Wark noted that a majority of 204 
patients reported strong negative emotions that included embarrassment and 205 
helplessness (27). The extent of these feelings was such that they recommended they 206 
should be addressed actively as part of their clinical management, an approach that is 207 
still recommended almost 50 years later (28). 208 
The incongruence between the fact that SSD patients still have access to one ‘good’ 209 
hearing ear and the chronic and complex burden that they report is perhaps why there is 210 
an increasing focus on the surgical restoration of hearing in their deaf ear (29) rather 211 
than traditional interventions that re-route sound between the ears (30). Early-phase 212 
trials have suggested that cochlear implantation is capable of restoring bilateral input and 213 
addressing, at least in part, the functional impairments of SSD (31, 32). However, as the 214 
field moves beyond demonstrations of clinical efficacy in the form that can be measured 215 
using controlled listening tests in the clinic or laboratory, increasing emphasis will 216 
inevitably be placed on conducting trials to measure broader impacts on quality of life to 217 
demonstrate the additional benefits to health it provides over currently available 218 
treatments. 219 
In designing these trials, one must first ask whether the intervention addresses one or 220 
more aspects of burden that are relevant to SSD patients, and what specific aspects of 221 
burden are being targeted. Such knowledge would ideally be supported by evidence from 222 
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early-phase trials so that the mechanism through which the intervention works is well 223 
understood. The choice of outcomes that are being measured would also need to be 224 
examined to ask whether they are considered by patients to be important for their health 225 
and wellbeing. Finally, outcome measures should be selected based evidence for their 226 
validity to measure those outcomes in these patients. Here we describe a research 227 
process that has been designed to address these questions in the field of SSD and to lay 228 
the groundwork for the development of a Core Outcome Set (Figure 1). 229 
 230 
** insert Figure 1 about here ** 231 
 232 
Fundamental to addressing many of these issues is a comprehensive understanding of 233 
the health condition itself. Little if any qualitative work around the burden imposed by 234 
SSD has been conducted since Giolas and Wark applied the Critical Incident Technique to 235 
study the functional consequences of SSD (27). This technique structures the interview 236 
around events that the patient recognises were affected by their hearing loss. Patient 237 
interviews were therefore conducted using a similar methodology to construct a 238 
hierarchical model of burden (33) based on patient-reported incidents and emerging 239 
themes from the transcripts. This qualitative approach provided a comprehensive 240 
characterisation of the impact of the health condition (34) and was initially used to 241 
assess whether interventions targeted aspects of health that are impaired by SSD. A 242 
systematic review identified those interventions and concluded that studies have 243 
focussed almost exclusively on intervening to improve functional impairments to speech 244 
perception and spatial hearing (35). However, the wide range and inconsistent use of 245 
patient-reported questionnaire instruments as outcome measures in existing trials meant 246 
that there is considerable uncertainty over what outcomes if any beyond the direct 247 
functional impairments to hearing were being targeted by these interventions (36). To 248 
address this uncertainty, a second systematic review is underway to identify what studies 249 
say they are trying to measure and to map those outcomes onto their use of specific 250 
measurement instruments (37). The content of the questionnaire instruments will be 251 
compared with the model of patient burden to assess whether they are targeting 252 
domains of health which are considered relevant by this patient group (23). The analysis 253 
will examine how successful these instruments are at targeting specific domains of health 254 
and therefore their suitability for use as outcome measures in the context of clinical trials 255 
(38). 256 
 257 
Relevance of existing questionnaires for assessing benefits of tinnitus 258 
treatments 259 
 260 
There is a substantial literature concerning self-assessment questionnaires for scaling the 261 
negative impacts of tinnitus. This literature shows that many different tinnitus-specific 262 
questionnaires have been used to assess treatment-related changes in tinnitus. For 263 
example, our review of clinical trials from 2006 to 2015 identified at least 78 different 264 
outcome instruments used in 228 trials; with 24 of those being different tinnitus-specific 265 
questionnaires. These were predominantly the Tinnitus Handicap Inventory (THI) (39) 266 
and the Tinnitus Questionnaire (TQ) (4, 40, 41). But even these two most popular 267 
instruments were used in only a minority of clinical research since we noted that usage 268 
was 15% and 7% out of 228 studies, for the THI and TQ respectively. We also note that 269 
these questionnaire instruments have predominantly been designed for screening and 270 
diagnostic purposes, not for measuring benefit from ENT/Audiological interventions. In 271 
particular, they measure multiple domains of patient burden. 272 
 273 
The tinnitus community widely acknowledges that a standard is needed to ensure that 274 
therapeutic benefit is measured much more consistently across studies, and that benefit 275 
is quantified using a measurement instrument that is fit for the purpose of outcome 276 
measurement (e.g. 42). A first attempt by Langguth and 28 other colleagues in 2006 277 
sought to develop a set of international recommendations on choice of instruments for 278 
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assessing the outcome from an intervention for tinnitus (43). The recommendations by 279 
this working group suggested four questionnaires; namely the Tinnitus Handicap 280 
Inventory (THI) (39), the Tinnitus Handicap Questionnaire (THQ) (44), the Tinnitus 281 
Questionnaire (TQ) (41) and the Tinnitus Reaction Questionnaire (TRQ) (45). These 282 
instruments were developed in diverse patient populations across the USA, UK, and 283 
Australia, but were not all developed for the same applications. In particular, while the 284 
THI, TQ and TRQ focus on aspects of psychological distress, the THQ was created to 285 
comprehensively measure the perceived degree of broad handicaps attributed to tinnitus 286 
(see Fackrell et al. (46) for a review). Nevertheless, they were chosen as they were the 287 
most widely used at the time, and had been translated for use in different languages and 288 
cultures. Their questions also broadly span the emotional impact of tinnitus, disability 289 
and handicap.  290 
 291 
** insert Figure 2 about here ** 292 
 293 
In making their interim recommendation, Langguth and colleagues commented that the 294 
THI, THQ, TQ and TRQ also share a common feature in that they attempt to quantify a 295 
combination of tinnitus-related distress, disability and handicap resulting in a large 296 
overlap of their items (43). Conceptual similarity is supported by statistical evidence for a 297 
high convergent validity between the global scores. For example, pairwise correlations 298 
between the THI, THQ, TQ and TRQ range from 0.74 to 0.89 (see Fackrell et al. (46) for 299 
a review). To explore conceptual equivalence in more detail we have conducted a fine-300 
grained evaluation of each individual questionnaire item to specify exactly what health 301 
concepts form the ingredients of each instrument. The findings from this evaluation are 302 
illustrated in Figure 2. The black cells indicate where the instrument contains at least one 303 
item that we judge to be asking about the corresponding tinnitus-related complaint. All 304 
questionnaire instruments contain items that ask about a diverse range of tinnitus-305 
related complaints covering all the major high-level categories of impact on everyday life, 306 
such as emotional impacts or activities and relationships. However, the patchwork 307 
highlights clear differences between instruments in terms of their specific item-level 308 
content. Some of these detailed differences could be clinically important for some 309 
individuals with critical gaps where an instrument entirely misses out questions on a 310 
particular type of complaint. For example, the impact of tinnitus on physical health is 311 
explored only in the TQ (‘bodily complaints’) and the THQ (‘ill health’). We have not yet 312 
compared the content of the instruments with available information about patient burden 313 
to assess whether they are targeting domains of health which are considered relevant by 314 
people with tinnitus (23). This analysis is planned. It will tell us how successful these 315 
instruments might be at targeting specific domains of health and therefore their 316 
suitability for use as outcome measures in the context of clinical trials of tinnitus, 317 
especially under certain circumstances (e.g. with a specific patient subtype, or for 318 
evaluating the outcome from a specific intervention). 319 
 320 
Langguth et al. (43) appreciated some of these limitations with the THI, THQ, TQ and 321 
TRQ and so the working group agreed that in the future, a “better” questionnaire was 322 
required. Since that time, a multi-item tinnitus questionnaire has been developed in the 323 
USA using a method to select items that optimized the overall responsiveness of the 324 
outcome score to treatment-related change (47). The resulting Tinnitus Functional Index 325 
(TFI) asks 25 questions about the intrusive of tinnitus, reduced sense of control, reduced 326 
quality of life, sleep disturbance, auditory difficulties, cognitive interference, interference 327 
with relaxation, and emotional distress, with pre-defined cut-offs for determining “not a 328 
problem”, “small problem”, “moderate problem”, “big problem”, and “very big problem”. 329 
When opting to use the TFI in other countries and cultures, it would be advisable to 330 
explore the content validity and severity grading in the new target population. 331 
 332 
DISCUSSION  333 
 334 
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These three examples illustrate different approaches to overcome the challenges of 335 
evaluating therapeutic benefit. In common, they all highlight the need to think critically 336 
about what it is one is seeking trying to measure. We end our review with some 337 
concluding remarks:  338 
 339 
 We have previously argued that it would be helpful to step away from using terms 340 
such as ‘handicap’ or ‘severity’ when naming a questionnaire instrument. These 341 
terms are not helpful to clinicians and researchers because they do not 342 
meaningfully describe exactly what health-related construct is being measured by 343 
the instrument (4). The development of the SPaRQ by Heffernan et al. provides a 344 
good example where the questionnaire name describes exactly what aspect of 345 
health the instrument claims to measure (22). 346 
 347 
 Although often questionnaire developers typically present psychometric validations 348 
of a questionnaire instrument, the word ‘validation’ is quite emotive. Validity is 349 
not a fixed property, but varies across populations and cultures. Its good practice 350 
therefore to keep an open mind and to evaluate any questionnaire instrument the 351 
first time its going to be used for a particular purpose and in a particular patient 352 
population. 353 
 354 
 At the end of the questionnaire evaluation, we might end up by failing to find any 355 
instruments which meet stringent contemporary standards of performance for 356 
outcome measures in clinical trials of SSD and tinnitus. What then? Clearly new 357 
research will be needed to modify an existing instrument, or create a new one 358 
from scratch. But what should we do in the meantime? Well, just because an 359 
instrument is not perfect does not necessarily mean that it should not be used. In 360 
this situation, clinicians can play an important role by collecting clinical data about 361 
their preferred instruments so that we have some evidence to inform decisions 362 
about good practice (content validity etc). We would also strongly support open 363 
data sharing as we believe that this is one of the best ways to make the most 364 
rapid progress the field.  365 
 366 
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Figure 1. Process for evaluating the choice of interventions and outcomes in clinical 498 
trials of single-sided deafness (SSD) and assessing the content validty of outcome 499 
measures.  500 
Figure 2. Item analysis of five tinnitus-specific questionnaires that have been used in 501 
clinical trials as instruments for measuring therapeutic outcomes. Black cells indicate that 502 
the questionnaire contains at least one item asking patients about that specific 503 
complaint. 504 
1 
 
REVIEW ARTICLE 1 
 2 
How do we know that our patients have benefitted from our ENT/Audiological 3 
interventions? 4 
 5 
ABSTRACT 6 
 7 
This short review article gives an introduction to some of the fundamental concepts and 8 
challenges facing measurement in hearing healthcare practice and research. The impact 9 
of hearing loss almost always extends beyond the sensory impairment itself, even when 10 
the measured degree of audiometric loss is mild. Yet, going beyond audibility, into the 11 
realm of measuring impact, takes us into a much more complex and less well-defined 12 
space. How does one therefore best measure the therapeutic benefit for evaluating 13 
efficacy or for clinical practice audit? Three case studies illustrate approaches to 14 
overcome such challenges. Each example highlights the importance of thinking critically 15 
about what it is one is seeking trying to measure, rather than selecting a questionnaire 16 
instrument based simply on its popularity or accessibility. We conclude by highlighting 17 
the important role that clinicians can play in collecting clinical data about their preferred 18 
instruments so that we have some evidence to inform decisions about good practice 19 
(content validity etc). We would also strongly support open data sharing as we believe 20 
that this is one of the best ways to make the most rapid progress the field. 21 
 22 
 23 
INTRODUCTION  24 
 25 
The purpose of this short article is to introduce the reader to some of the fundamental 26 
concepts and challenges facing measurement in healthcare practice and research. The 27 
concept of measurement will perhaps be most familiar to the reader in the context of the 28 
audiogram. The audiogram plots air conduction threshold for tones presented to either 29 
ear and is useful for determining hearing sensitivity. Pure-tone averages can be 30 
interpreted with respect to standard category boundaries, such as mild hearing loss (26-31 
40 dB A) (1). The impact of hearing loss almost always extends beyond the sensory 32 
impairment itself, even when the measured degree of audiometric loss is mild. It is well 33 
known that residual hearing is not related in any straightforward way to the burden of 34 
disability experienced by a person with hearing loss (2). Going beyond audibility, into the 35 
realm of measuring impact, takes us into a much more complex and less well-defined 36 
space. For example, mild-to-moderate hearing loss has been reported by patients to 37 
interfere with hearing environmental sounds, listening, communicating, speaking, and it 38 
can negatively affect family life, social relationships, and ability to work. On a personal 39 
level, the negative stigma can affect personal identity, promote a sense of isolation, 40 
negative emotions such as frustration, distress and depression. Hearing loss can also 41 
increase the effort required for listening and communicating causing fatigue (3). The 42 
impact of hearing-related problems, such as tinnitus, similarly spans a wide array of 43 
psychological and social dimensions (4). 44 
 45 
No gold standard measure Instead of clinician-administered tests, the impacts of 46 
hearing loss and tinnitus are often assessed using a patient-reported instrument such as 47 
a questionnaire. However, there are no gold standards. This is reflected in the lack of 48 
consensus in the selection of questionnaires for hearing studies (4, 5).  49 
 50 
Diversity of patient complaints Given the diversity of reported complaints, every 51 
patient presents with a complex array of symptoms and functional impacts. Moreover, 52 
any clinician or researcher who has worked with people with a hearing-related problem 53 
will appreciate that every individual’s experience is a very personal one. In practical 54 
terms, while one person’s primary motivation for seeking medical help might be because 55 
their hearing-related problem means that they no longer enjoy socialising with friends 56 
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down the pub, for another it may be because their ability to play in an orchestra is 57 
hindered, while for another hearing loss might make it difficult watching television 58 
comfortably with their spouse. The impact of hearing loss is therefore a construct that is 59 
very individualised and personal. 60 
  61 
Practical challenges This situation presents the ENT/Audiology professional with two 62 
major practical challenges; the first concerns how to comprehensively assess a patient 63 
for a precise clinical diagnosis, and the second concerns how to measure the therapeutic 64 
benefit for evaluating efficacy or for clinical practice audit. With some degree of success, 65 
the challenge for clinical diagnosis has been resolved by creating multi-attribute 66 
questionnaire instruments whose scores can be used to discriminate between individuals. 67 
For example, the Hearing Handicap Inventory for the Elderly (HHIE) asks 25 questions 68 
about the emotional consequences of hearing impairment, social and situational effects 69 
(6), with pre-defined cut-offs for determining “no handicap”, “mild to moderate 70 
handicap” and “significant handicap”.  71 
 72 
However, the solution to the first challenge tends to be incompatible with evaluating 73 
therapeutic benefit. This is because questionnaire items that discriminate well between 74 
different patients at the diagnostic appointment are not necessarily sensitive to 75 
evaluating changes over time within the same patient (7). And it is difficult to design a 76 
questionnaire instrument that is both discriminative and evaluative. To illustrate this with 77 
an example, tinnitus-related emotional distress and auditory difficulties might both 78 
discriminate one patient from another, but only one of these might be responsive to 79 
treatment (e.g. hearing aids should reduce auditory difficulties, but might not reduce 80 
distress). Averaging the benefit scores for these components could therefore compromise 81 
the sensitivity of an aggregated score to measuring treatment-related change. As a 82 
general rule, questionnaire instruments that successfully measure therapeutic benefit in 83 
different situations tend to be those with good statistical properties that enable the 84 
clinician or investigator to interpret specific complaints rather than a global non-specific 85 
construct like “severity” or “handicap” (8). 86 
 87 
In this short review, we present three case studies which illustrate approaches to 88 
overcome the challenges of evaluating therapeutic benefit. These examples highlight the 89 
need to think critically about what it is one is seeking trying to measure, rather than 90 
selecting a questionnaire instrument based simply on its popularity or accessibility.  91 
 92 
Measuring psychosocial functioning of adults with mild-to-moderate hearing 93 
loss 94 
 95 
The International Classification of Functioning, Disability, and Health (ICF) is a 96 
biopsychosocial framework designed to standardise the description, measurement, 97 
clinical assessment, and teaching of functioning, disability, and health for researchers, 98 
clinicians, clinical educators, and policy-makers around the world (9). The ICF consists of 99 
three primary domains of patient burden: (1) physical impairments, or deficits in body 100 
functions or body structures, (2) activity limitations, or problems executing tasks and 101 
actions, and (3) participation restrictions, or problems with involvement in life situations. 102 
These domains are influenced by both environmental factors and personal factors (9, 103 
10). The ICF also includes a comprehensive taxonomy of categories of functioning (e.g. 104 
listening, education, self-care). The categories of functioning most relevant to hearing 105 
loss have been identified by a large, cross-cultural, mixed-methods study (10). 106 
Therefore, the ICF could be used in the future to standardise the measurement of 107 
individuals with hearing loss in clinical practice or in research.  108 
 109 
The domain of participation restrictions is thought to be the most difficult of the ICF 110 
domains to measure (11). One obstacle is that the conceptualisation of participation 111 
restrictions is imprecise and inconsistent (12). The WHO (2001) definition above is rather 112 
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broad, which means that it is difficult to distinguish participation restrictions from related 113 
constructs, such as activity limitations and quality of life (13). Also, there is no consensus 114 
regarding the categories of functioning that should be included in a participation 115 
restrictions measurement instrument (14). Another obstacle is that different people 116 
participate in different ways, depending on their personal preferences and circumstances. 117 
It is difficult to capture such a highly individual construct in one standardised tool (13). 118 
One solution is to develop different questionnaire instruments for different subgroups 119 
(15). However, this can impede comparisons across groups and across studies. Another 120 
solution is to create patient-generated measurement tools that permit respondents to 121 
personalise their content. However, personalised instruments may not be well suited to 122 
the grouping of scores or comparisons across time periods and across individuals. Also, 123 
they can be difficult for some respondents to understand and complete (16). Another 124 
approach is to obtain counts of social interaction frequency or social network size (17). 125 
However, such measures fail to acknowledge that the quality of social contacts can be 126 
more important for wellbeing than quantity of social contacts (18).  127 
 128 
** insert Table 1 about here ** 129 
 130 
Here, we provide a case study of the utilisation of best practice techniques to develop a 131 
hearing-specific measure of participation. Best practice techniques, which include 132 
qualitative methodologies (e.g. cognitive interviews) and modern psychometric analysis 133 
(e.g. Rasch analysis), are necessary for the creation of gold standard measures. 134 
However, to date, these techniques have seldom been employed in the development of 135 
hearing-specific measures. 136 
 137 
The questionnaire we developed, entitled the Social Participation Restrictions 138 
Questionnaire (SPaRQ), was designed to serve as an outcome measure in either research 139 
or clinical practice. The SPaRQ consists of a 9-item subscale measuring social behaviours 140 
(e.g. difficulties with social interactions) and a 10-item subscale measuring social 141 
perceptions (e.g. feelings of isolation). It uses an 11-point response scale (0=completely 142 
disagree, 10=completely agree) because a broad range of response options are 143 
considered to enhance responsiveness (19). The SPaRQ was designed by conducting a 144 
series of qualitative and quantitative studies (see Table 1) in accordance with 145 
internationally-recognised guidelines from the questionnaire development literature (20, 146 
21). Our aim was to ensure that the measurement properties of the SPaRQ met the 147 
standards required of outcome measures used in clinical practice and in clinical trials 148 
(21). 149 
 150 
The first step was to create a precise conceptual model of hearing-related participation 151 
restrictions and to determine the categories of functioning that should be included in the 152 
measure by (1) reviewing the literature, including existing questionnaire instruments and 153 
the ICF, and (2) interviewing adults with hearing loss and hearing healthcare 154 
professionals (22). The second step was to evaluate the content validity of the SPaRQ, 155 
including its relevance, clarity, acceptability, and potential responsiveness, by (1) 156 
conducting cognitive interviews with adults with hearing loss and (2) surveying hearing 157 
healthcare professionals. Qualitative research with key stakeholders is an often 158 
overlooked but essential component of questionnaire development, at it ensures that the 159 
instrument adequately captures the respondents‘ experiences, uses everyday language, 160 
and is easy to administer and complete (23). The third step was to assess the 161 
psychometric properties of the SPaRQ by applying (1) Rasch analysis and (2) traditional 162 
(i.e. Classical Test Theory) psychometric analysis to data collected from adults with 163 
hearing loss. Whilst most hearing-specific questionnaires have been developed using 164 
traditional psychometric analysis alone, a modern approach (i.e. Rasch analysis or Item 165 
Response Theory) should also be applied because it enables all the relevant psychometric 166 
properties (e.g. unidimensionality, differential item functioning) to be adequately 167 
assessed (24). The outcome of this rigorous development process was the production of 168 
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a questionnaire that possesses an array of good measurement properties. For instance, 169 
each subscale was found to be unidimensional, which means that all of the items within a 170 
subscale measure the same construct, and well-targeted, which means that the 171 
subscales have high measurement precision and capture a wide range of participation 172 
restrictions. There was also evidence to support the convergent validity of the subscales 173 
with each one displaying strong, positive correlations with a hearing-specific disability 174 
measure and moderate, positive correlations with a generic disability measure and a 175 
mental health screening tool. Responsiveness of the SPaRQ is yet to be examined, but 176 
this is planned for future research. 177 
 178 
One limitation of this research is that it adds another questionnaire to the range of 179 
existing questionnaires that are currently being used in hearing research (5). However, it 180 
is sometimes necessary to develop new measures in accordance with the latest best 181 
practice recommendations in order to address the lack of gold standard measures in the 182 
field. In the future, researchers and clinicians would benefit from the introduction of 183 
guidelines to help them to identify high quality measures that are appropriate for their 184 
purposes.   185 
 186 
 187 
Relevance of existing questionnaires for assessing burden of single-sided 188 
deafness (SSD) 189 
 190 
At face value, single-sided deafness (SSD) would appear to be a form of hearing loss 191 
where the task of determining whether or not a patient has benefitted from an 192 
intervention should be relatively straightforward. Lack of hearing on one side of the head 193 
would be expected to hinder access to acoustic information in that hemifield and disrupt 194 
the ability to segregate information from different sources (25). One might also be 195 
tempted to assume that relevant interventions for this patient group are those that 196 
address these impaired listening skills, and benefit should be measured in terms of the 197 
extent to which they have restored or improved such skills. However, some of the 198 
earliest published observations about these patients remarked on the unexpected degree 199 
of burden that impairments to these listening skills impose on the patient. Harford and 200 
Barry noted “the persistence and earnestness of reports from unilaterally hearing-201 
impaired individuals stating serious difficulty encountered in many common listening 202 
situations” (26). Early work also suggested a breadth and depth of burden that one might 203 
not predict from these functional difficulties. Giolas and Wark noted that a majority of 204 
patients reported strong negative emotions that included embarrassment and 205 
helplessness (27). The extent of these feelings was such that they recommended they 206 
should be addressed actively as part of their clinical management, an approach that is 207 
still recommended almost 50 years later (28). 208 
The incongruence between the fact that SSD patients still have access to one ‘good’ 209 
hearing ear and the chronic and complex burden that they report is perhaps why there is 210 
an increasing focus on the surgical restoration of hearing in their deaf ear (29) rather 211 
than traditional interventions that re-route sound between the ears (30). Early-phase 212 
trials have suggested that cochlear implantation is capable of restoring bilateral input and 213 
addressing, at least in part, the functional impairments of SSD (31, 32). However, as the 214 
field moves beyond demonstrations of clinical efficacy in the form that can be measured 215 
using controlled listening tests in the clinic or laboratory, increasing emphasis will 216 
inevitably be placed on conducting trials to measure broader impacts on quality of life to 217 
demonstrate the additional benefits to health it provides over currently available 218 
treatments. 219 
In designing these trials, one must first ask whether the intervention addresses one or 220 
more aspects of burden that are relevant to SSD patients, and what specific aspects of 221 
burden are being targeted. Such knowledge would ideally be supported by evidence from 222 
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early-phase trials so that the mechanism through which the intervention works is well 223 
understood. The choice of outcomes that are being measured would also need to be 224 
examined to ask whether they are considered by patients to be important for their health 225 
and wellbeing. Finally, outcome measures should be selected based evidence for their 226 
validity to measure those outcomes in these patients. Here we describe a research 227 
process that has been designed to address these questions in the field of SSD and to lay 228 
the groundwork for the development of a Core Outcome Set (Figure 1). 229 
 230 
** insert Figure 1 about here ** 231 
 232 
Fundamental to addressing many of these issues is a comprehensive understanding of 233 
the health condition itself. Little if any qualitative work around the burden imposed by 234 
SSD has been conducted since Giolas and Wark applied the Critical Incident Technique to 235 
study the functional consequences of SSD (27). This technique structures the interview 236 
around events that the patient recognises were affected by their hearing loss. Patient 237 
interviews were therefore conducted using a similar methodology to construct a 238 
hierarchical model of burden (33) based on patient-reported incidents and emerging 239 
themes from the transcripts. This qualitative approach provided a comprehensive 240 
characterisation of the impact of the health condition (34) and was initially used to 241 
assess whether interventions targeted aspects of health that are impaired by SSD. A 242 
systematic review identified those interventions and concluded that studies have 243 
focussed almost exclusively on intervening to improve functional impairments to speech 244 
perception and spatial hearing (35). However, the wide range and inconsistent use of 245 
patient-reported questionnaire instruments as outcome measures in existing trials meant 246 
that there is considerable uncertainty over what outcomes if any beyond the direct 247 
functional impairments to hearing were being targeted by these interventions (36). To 248 
address this uncertainty, a second systematic review is underway to identify what studies 249 
say they are trying to measure and to map those outcomes onto their use of specific 250 
measurement instruments (37). The content of the questionnaire instruments will be 251 
compared with the model of patient burden to assess whether they are targeting 252 
domains of health which are considered relevant by this patient group (23). The analysis 253 
will examine how successful these instruments are at targeting specific domains of health 254 
and therefore their suitability for use as outcome measures in the context of clinical trials 255 
(38). 256 
 257 
Relevance of existing questionnaires for assessing benefits of tinnitus 258 
treatments 259 
 260 
There is a substantial literature concerning self-assessment questionnaires for scaling the 261 
negative impacts of tinnitus. This literature shows that many different tinnitus-specific 262 
questionnaires have been used to assess treatment-related changes in tinnitus. For 263 
example, our review of clinical trials from 2006 to 2015 identified at least 78 different 264 
outcome instruments used in 228 trials; with 24 of those being different tinnitus-specific 265 
questionnaires. These were predominantly the Tinnitus Handicap Inventory (THI) (39) 266 
and the Tinnitus Questionnaire (TQ) (4, 40, 41). But even these two most popular 267 
instruments were used in only a minority of clinical research since we noted that usage 268 
was 15% and 7% out of 228 studies, for the THI and TQ respectively. We also note that 269 
these questionnaire instruments have predominantly been designed for screening and 270 
diagnostic purposes, not for measuring benefit from ENT/Audiological interventions. In 271 
particular, they measure multiple domains of patient burden. 272 
 273 
The tinnitus community widely acknowledges that a standard is needed to ensure that 274 
therapeutic benefit is measured much more consistently across studies, and that benefit 275 
is quantified using a measurement instrument that is fit for the purpose of outcome 276 
measurement (e.g. 42). A first attempt by Langguth and 28 other colleagues in 2006 277 
sought to develop a set of international recommendations on choice of instruments for 278 
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assessing the outcome from an intervention for tinnitus (43). The recommendations by 279 
this working group suggested four questionnaires; namely the Tinnitus Handicap 280 
Inventory (THI) (39), the Tinnitus Handicap Questionnaire (THQ) (44), the Tinnitus 281 
Questionnaire (TQ) (41) and the Tinnitus Reaction Questionnaire (TRQ) (45). These 282 
instruments were developed in diverse patient populations across the USA, UK, and 283 
Australia, but were not all developed for the same applications. In particular, while the 284 
THI, TQ and TRQ focus on aspects of psychological distress, the THQ was created to 285 
comprehensively measure the perceived degree of broad handicaps attributed to tinnitus 286 
(see Fackrell et al. (46) for a review). Nevertheless, they were chosen as they were the 287 
most widely used at the time, and had been translated for use in different languages and 288 
cultures. Their questions also broadly span the emotional impact of tinnitus, disability 289 
and handicap.  290 
 291 
** insert Figure 2 about here ** 292 
 293 
In making their interim recommendation, Langguth and colleagues commented that the 294 
THI, THQ, TQ and TRQ also share a common feature in that they attempt to quantify a 295 
combination of tinnitus-related distress, disability and handicap resulting in a large 296 
overlap of their items (43). Conceptual similarity is supported by statistical evidence for a 297 
high convergent validity between the global scores. For example, pairwise correlations 298 
between the THI, THQ, TQ and TRQ range from 0.74 to 0.89 (see Fackrell et al. (46) for 299 
a review). To explore conceptual equivalence in more detail we have conducted a fine-300 
grained evaluation of each individual questionnaire item to specify exactly what health 301 
concepts form the ingredients of each instrument. The findings from this evaluation are 302 
illustrated in Figure 2. The black cells indicate where the instrument contains at least one 303 
item that we judge to be asking about the corresponding tinnitus-related complaint. All 304 
questionnaire instruments contain items that ask about a diverse range of tinnitus-305 
related complaints covering all the major high-level categories of impact on everyday life, 306 
such as emotional impacts or activities and relationships. However, the patchwork 307 
highlights clear differences between instruments in terms of their specific item-level 308 
content. Some of these detailed differences could be clinically important for some 309 
individuals with critical gaps where an instrument entirely misses out questions on a 310 
particular type of complaint. For example, the impact of tinnitus on physical health is 311 
explored only in the TQ (‘bodily complaints’) and the THQ (‘ill health’). We have not yet 312 
compared the content of the instruments with available information about patient burden 313 
to assess whether they are targeting domains of health which are considered relevant by 314 
people with tinnitus (23). This analysis is planned. It will tell us how successful these 315 
instruments might be at targeting specific domains of health and therefore their 316 
suitability for use as outcome measures in the context of clinical trials of tinnitus, 317 
especially under certain circumstances (e.g. with a specific patient subtype, or for 318 
evaluating the outcome from a specific intervention). 319 
 320 
Langguth et al. (43) appreciated some of these limitations with the THI, THQ, TQ and 321 
TRQ and so the working group agreed that in the future, a “better” questionnaire was 322 
required. Since that time, a multi-item tinnitus questionnaire has been developed in the 323 
USA using a method to select items that optimized the overall responsiveness of the 324 
outcome score to treatment-related change (47). The resulting Tinnitus Functional Index 325 
(TFI) asks 25 questions about the intrusive of tinnitus, reduced sense of control, reduced 326 
quality of life, sleep disturbance, auditory difficulties, cognitive interference, interference 327 
with relaxation, and emotional distress, with pre-defined cut-offs for determining “not a 328 
problem”, “small problem”, “moderate problem”, “big problem”, and “very big problem”. 329 
When opting to use the TFI in other countries and cultures, it would be advisable to 330 
explore the content validity and severity grading in the new target population. 331 
 332 
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These three examples illustrate different approaches to overcome the challenges of 335 
evaluating therapeutic benefit. In common, they all highlight the need to think critically 336 
about what it is one is seeking trying to measure. We end our review with some 337 
concluding remarks:  338 
 339 
 We have previously argued that it would be helpful to step away from using terms 340 
such as ‘handicap’ or ‘severity’ when naming a questionnaire instrument. These 341 
terms are not helpful to clinicians and researchers because they do not 342 
meaningfully describe exactly what health-related construct is being measured by 343 
the instrument (4). The development of the SPaRQ by Heffernan et al. provides a 344 
good example where the questionnaire name describes exactly what aspect of 345 
health the instrument claims to measure (22). 346 
 347 
 Although often questionnaire developers typically present psychometric validations 348 
of a questionnaire instrument, the word ‘validation’ is quite emotive. Validity is 349 
not a fixed property, but varies across populations and cultures. Its good practice 350 
therefore to keep an open mind and to evaluate any questionnaire instrument the 351 
first time its going to be used for a particular purpose and in a particular patient 352 
population. 353 
 354 
 At the end of the questionnaire evaluation, we might end up by failing to find any 355 
instruments which meet stringent contemporary standards of performance for 356 
outcome measures in clinical trials of SSD and tinnitus. What then? Clearly new 357 
research will be needed to modify an existing instrument, or create a new one 358 
from scratch. But what should we do in the meantime? Well, just because an 359 
instrument is not perfect does not necessarily mean that it should not be used. In 360 
this situation, clinicians can play an important role by collecting clinical data about 361 
their preferred instruments so that we have some evidence to inform decisions 362 
about good practice (content validity etc). We would also strongly support open 363 
data sharing as we believe that this is one of the best ways to make the most 364 
rapid progress the field.  365 
 366 
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Figure 1. Process for evaluating the choice of interventions and outcomes in clinical 498 
trials of single-sided deafness (SSD) and assessing the content validty of outcome 499 
measures.  500 
Figure 2. Item analysis of five tinnitus-specific questionnaires that have been used in 501 
clinical trials as instruments for measuring therapeutic outcomes. Black cells indicate that 502 
the questionnaire contains at least one item asking patients about that specific 503 
complaint. 504 
Figure 1 Click here to download Figure (TIFF, PDF, Word Doc, PPT, or
EPS files are acceptable) Figure 1.tif
Figure 2 Click here to download Figure (TIFF, PDF, Word Doc, PPT, or
EPS files are acceptable) Figure 2.tif
Table 1. Development of the Social Participation Restrictions Questionnaire 
(SPaRQ) 
Study Main Aim Method Data Analysis 
1 Conceptualise 
participation 
restrictions in adults 
with hearing loss  
 
Generate content for 
the first SPaRQ 
prototype 
Semi-structured 
interviews with 25 adults 
with hearing loss and 
9 hearing healthcare 
professionals 
Deductive thematic 
analysis 
2 Evaluate the content 
validity of the first 
SPaRQ prototype 
Cognitive interviews 14 
adults with hearing loss 
 
Online survey of 20 
hearing healthcare 
professionals  
Deductive analysis 
using a taxonomy of 
respondent problems  
 
Descriptive statistics 
3 Assess the 
psychometric properties 
of the second SPaRQ 
prototype 
Questionnaire completed 
by 279 adults with 
hearing loss 
Rasch analysis  
4 Assess the 
psychometric properties 
of the finalised SPaRQ 
Questionnaire completed 
by 102 adults with 
hearing loss 
Traditional 
psychometric analysis 
 
Table 1
